Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 2:12:854402.
doi: 10.3389/fonc.2022.854402. eCollection 2022.

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

Sebastian Rubino  1 , Daniel E Oliver  2 , Nam D Tran  1 , Michael A Vogelbaum  1 , Peter A Forsyth  1 , Hsiang-Hsuan Michael Yu  2 , Kamran Ahmed  2 , Arnold B Etame  1
Affiliations
Review

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

Sebastian Rubino et al. Front Oncol. .

Abstract

Brain metastases are the most common form of brain cancer. Increasing knowledge of primary tumor biology, actionable molecular targets and continued improvements in systemic and radiotherapy regimens have helped improve survival but necessitate multidisciplinary collaboration between neurosurgical, medical and radiation oncologists. In this review, we will discuss the advances of targeted therapies to date and discuss findings of studies investigating the synergy between these therapies and stereotactic radiosurgery for non-small cell lung cancer, breast cancer, melanoma, and renal cell carcinoma brain metastases.

Keywords: SRS; brain metastases; breast cancer; melanoma; non-small cell lung cancer; renal cell carcinoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Nayak L, Lee EQ, Wen PY. Epidemiology of Brain Metastases. Curr Oncol Rep (2012) 14(1):48–54. doi: 10.1007/s11912-011-0203-y - DOI - PubMed
    1. Mitchell DK, Kwon HJ, Kubica PA, Huff WX, O'Regan R, Dey M. Brain Metastases: An Update on the Multi-Disciplinary Approach of Clinical Management. Neurochirurgie (2022) 68(1):69–85. doi: 10.1016/j.neuchi.2021.04.001 - DOI - PMC - PubMed
    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol (2004) 22(14):2865–72. doi: 10.1200/JCO.2004.12.149 - DOI - PubMed
    1. Wen PY, Loeffler JS. Management of Brain Metastases. Oncol (Williston Park) (1999) 13(7):941–54, 57-61; discussion 61-2, 9. - PubMed
    1. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. . Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol (2022) 40(5):492–516. doi: 10.1200/JCO.21.02314 - DOI - PubMed

LinkOut - more resources